Exocin is for the topical treatment of external eye infections such as conjunctivitis.
Price: ₵120.00
EXOCIN (OFLOXACIN) EYE DROP
Why do you need to give this medicine? Exocin is for the topical treatment of external eye infections such as conjunctivitis.
INGREDIENTS
Contains Ofloxacin 0.3 % v/w.
ADDED INFORMATION
This medicine contains Benzalkonium chloride, sodium chloride, hydrochloric acid and sodium hydroxide (for pH adjustment) and purified water. Benzalkonium chloride is a preservative which may be absorbed by soft contact lenses and may change the colour of the contact lenses. It is recommended that you do not wear contact lenses whilst being treated with this product. However, there may be situations where use of contact lenses is unavoidable. In these situations, you should remove contact lenses before using this medicine and put them back 15 minutes afterwards. Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye).
DOSAGE
Adults: The usual dose is one or two drops three or four times daily in the affected eye(s).
POSSIBLE SIDE EFFECTS
Eye pain, eye discomfort, swelling around the eyes, blurred vision, dry eyes, redness of the eye, burning sensation of eyes, eye irritation.
WARNINGS AND PRECAUTIONS
Use of contact lenses is not recommended in patients receiving treatment for an eye infection. Exocin potentially increases sensitivity to sunlight. You should avoid exposure to direct sunlight or sun during use of Exocin.
Exocin should not be used by children or adolescents.
It is recommended that Exocin is not used during pregnancy or if you are breastfeeding. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
STORAGE
Store at a temperature that doesn’t exceed 25°C. Keep out of the reach and sight of children.
Do you have any questions? Do not hesitate to contact us.
Reviews
There are no reviews yet.